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Abstract 
Background 
 The incidence of Clostridium difficile infection (CDI) has been increasing in 
communities and healthcare associated settings in the last 25-50 years. Clostridium difficile is a 
Gram-positive bacteria found in the large bowel or colon that causes mild to severe intestinal 
conditions and sometimes death. The primary risk factors for development of CDI include 
healthcare exposure and recent antimicrobial use. The purpose of this study is to compare risk 
factors associated with CDI occurring in the Community to those associated with Healthcare 
Facility Associated CDI in the metro Atlanta population from September 1, 2009 – April 30, 
2011. 
Methods 
 Patients were identified through C. difficile surveillance program of the Georgia 
Emerging Infections Program (EIP). Prospective, population based, laboratory based surveillance 
for all positive C. difficile cases in the Georgia Health District 3 (HD3). Due to high volume of 
positive CDI, a stratified random 1:3 sampling scheme is used and cases are stratified by age and 
gender. Identified sampled cases undergo a retrospective Case Report Form completion and are 
classified in to three classifications: Community Associated (CA), Community Onset-Healthcare 
Facility Associated (CO-HCFA), and Healthcare Facility Onset (HCFO). An additional 1:10 
sampling occurs for HCFO cases. Due to the sampling scheme, for this analysis CO-HCFA and 
HCFO cases were combined to make a Healthcare Facility Associated (HCFA) classification. 
Using SAS, a logistic regression analysis was performed to compare the associated risks between 
CA and HCFA classifications.  
Results 
 The rate of CDI in the HD3 counties in Georgia is 84 per 100,000. The median age of 
infection is 63 and the age range in this study is 1 to 102 years old. CA cases represented 38% of 
the sampled population. CDI cases 65 and older were more likely to have a Healthcare 
association compared to CA-CDI cases (p <0.01). HFCA-CDI cases were more likely to be 
exposed to the following antibiotics Cephalosporins, Metronidazole, and Vancomycin ( all p 
values <0.01). In addition, HCFA-CDI cases were more likely to have the following underlying 
conditions Cardiovascular, Neurological, Tumors, Other Chronic Conditions, and Diabetes (all p 
values <0.0001) compared to CA-CDI Cases. HCFA-CDI cases had individuals that had two or 
more underlying conditions and had more individuals that were taking two or more antibiotics 14 
days prior to a positive stool culture compared to CA-CDI cases (both chi square <0.0001).  
Conclusion 
 CDI is prevalent in the metro Atlanta population and this study identifies the risk factors 
that are associated with Community Associated Cases and Healthcare Facility Associated Cases. 
Based on this population sample, antibiotics use and underlying conditions appear to be 
significant factors in HCFA-CDI cases compared to CA-CDI cases. This study supports 
literature about CDI and antimicrobial use and looks further in to the role underlying conditions 
play as a risk factor for HCFA-CDI cases. 
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CHAPTER I 
Introduction  
The incidence of Clostridium difficile infection (CDI) has been increasing in 
communities and healthcare associated settings in the last 25-50 years. Clostridium difficile is a 
Gram-positive bacteria found in the large bowel or colon that causes mild to severe intestinal 
conditions and sometimes death. Exposures to healthcare settings and antibiotic use have most 
often been cited as risk factors for CDI. In recent years, CDI has become more frequent, more 
severe, and more difficult to treat. Each year tens of thousands of people in the United States get 
sick from C. difficile, including some otherwise healthy people who are not hospitalized or 
taking antibiotics (Kyne, Hamel, Polavaram, & Kelly, 2002).  Mild illness caused by CDI may 
resolve by discontinuing antibiotics. Severe symptoms require treatment with an antibiotic 
targeting C. difficile (Owens, Donskey, Gaynes, Loo, & Muto, 2008).  The most common 
symptoms of mild to moderate C. difficile infection are watery diarrhea occurring three or more 
times a day for two or more days and mild abdominal cramping and tenderness (McDonald et al., 
2005). More severe CDI can lead to colitis, pseudomembranous colitis, and death (Kyne et al., 
2002).  
Pathogenic strains of C. difficile produce two distinct toxins. Toxin A is an enterotoxin, 
and toxin B is a cytotoxin. Both are high-molecular weight proteins capable of binding to 
specific receptors on the intestinal mucosal cells. (Nusrat et al., 2001). CDI occurs from a 
disturbance of the normal bacterial flora of the colon, acquisition of C. difficile, and the release 
of toxins that cause mucosal inflammation and damage (Gronczewski et al., 2012). Antibiotic 
therapy is the key factor that alters the colonic flora (Owens et al., 2008). Acquisition occurs via 
the fecal – oral route (Jarvis, 1996) leading to either asymptomatic colonization or clinical 
disease. C. difficile forms heat-resistant spores that can persist in the environment for several 
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months to years. The hand picks up the bacteria from a surface that has minute amounts of fecal 
contamination and the bacterium finds its way to the mouth via touch, food, etc. However, unlike 
many other bacteria, C. difficile spores can survive in both hot and cold temperatures and is 
resistant to the action of many chemicals, including the alcohol-based hand sanitizers which 
makes killing this bacteria difficult (McDonald, 2005). Normal gut flora resists colonization and 
overgrowth with C. difficile. Transmission of C. difficile occurs primarily in healthcare facilities, 
where the environmental contaminations by C. difficile spores and exposure to antimicrobial 
drugs are common. Antibiotic use suppresses the normal flora allowing proliferation of C. 
difficile  (Gronczewski et al., 2012; McDonald, 2005). However, C. difficile is no longer limited 
to healthcare environments and is increasing in the community in both healthcare and non-
healthcare exposed populations (Henrich, Krakower, Bitton, & Yokoe, 2009).  
The primary risk factors for development of C. difficile include healthcare exposure and 
recent antimicrobial use. Additional risk factors for acquisition include age greater than 65 and 
severe underlying illness. Healthcare exposure can occur from cross contamination situations. As 
C. difficile spores are dispersed by fecal matter, patient, staff, and environmental hygiene is vital 
(Jarvis, 1996). Staff cannot always avoid coming in contact with C. difficile spores and the main 
agent of transmission is often hands. In addition, another vehicle for transmission is hospital, 
long term care facility, or nursing home toilets. Environmental cleaning is important in 
healthcare facilities and the use of special disinfectants are needed because C. difficile  spores are 
hardy and can survive for several months and are not killed by many cleaning agents alone
 
(McDonald, 2005). 
 
For most healthy people, C. difficile does not pose a health risk. The elderly, those with 
other illness, or taking antibiotics are at greater risk of infection. Using antibiotics increases the 
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chance of developing C. difficile infection. Antibiotics alter the normal levels of protective 
bacteria found in the intestines and colon. When the balance of the normal flora in our intestines 
and colon has been disrupted, C. difficile bacteria have the chance to thrive and produce toxins
 
(Warny et al., 2005). These toxins cause inflammation of the bowel and cause mild to severe 
diarrhea. Age is also a risk factor for the development of disease. People ages 65 years and older 
are 10 times more likely to become infected with C. difficile compared to those less than 65 
(Lambert, Dyck, Thompson, & Hammond, 2009). 
C. difficile is very common in the Atlanta, Georgia metropolitan population based upon a 
population-based surveillance system established by the Georgia Emerging Infections Program 
in 2009. C. difficile cases are identified through toxin positive stool cultures, identified in 
hospital or reference laboratories. Eligibility requirements include being a resident of Health 
District 3 and being over 1 year of age on collection date. Population-based surveillance allows a 
comparison of Community Associated and Healthcare Facility Associated cases of CDI. 
Although risk factors for healthcare associated infection have been established, risk factors for 
community onset disease are less well understood. Active, population-based surveillance for CDI 
provides longitudinal study of the incidence rates of CDI Unlike many other studies of CDI, 
prospective, population-based surveillance is not restricted to outbreak investigation but rather, 
all reported cases between September 2009 and April 2011 occurring in Atlanta Health District 3 
can be analyzed. 
CDI surveillance data collected from September 1, 2009 to April 30, 2011 from 8 
counties in metropolitan Atlanta, Georgia (Clayton, Cobb, Dekalb, Douglas, Gwinnett, Fulton, 
Newton, and Rockdale) were utilized for this project known as Health District 3 (HD3). An 
analysis was conducted to compare risk factors associated with C. difficile infections occurring in 
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the Community to those associated with Healthcare Facility Associated CDI Cases. The 
objectives of this investigation were to examine the antibiotic use and underlying conditions 
associated with CDI. In addition, age over 65 is a risk factor, so age will be considered in the 
analysis while comparing the two groups. This analysis will assist in better understanding CDI in 
a described population and determine whether there are differences between Community 
Associated infections and Healthcare Facility Associated infections.  
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CHAPTER II 
Literature Review 
Clostridium difficile Background 
 Clostridium difficile was first described in 1935 as part of the intestinal microflora in 
neonates. Although the severe form of C. difficile disease was first discovered in 1893, the 
pathogen was not actually identified as the causative agent of human disease until 1978 
(McDonald et al).  C. difficile is an anaerobic, spore-forming, toxigenic bacteria that is the most 
commonly recognized cause of infectious nosocomial diarrhea and one of the most common 
healthcare-associated pathogens (Campbell et al., 2009). C. difficile infection (CDI) is a toxin-
mediated intestinal disease, and extra-intestinal manifestations are rare. C. difficile is recognized 
as the main cause of infectious diarrhea that develops in patients after hospitalization and 
antimicrobial treatment (Thomas et al). The association between antimicrobial therapy and CDI 
is very strong, as C. difficile can only colonize the gut if the normal intestine microbiota is 
disturbed or absent (Gronczewski et al). A case of C. difficile incidence (CDI) is defined as a 
positive toxin or nucleic acid C. difficile assay (Cohen et al., 2010). C. difficile can be detected in 
stool specimens.  
 
Clinical Manifestation 
 The clinical manifestations of infection with toxin-producing strains of C. difficile  range 
from asymptomatic carriage, mild or moderate diarrhea, to fulminant and sometimes fatal 
pseudomembranous colitis (Barbut et al., 1996; Cohen et al., 2010). Several studies have shown 
that 50% or more of hospital patients colonized by C. difficile are asymptomatic carriers, 
possibly reflecting natural immunity (Kyne et al., 2002). Symptoms of CDI usually begin soon 
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after acquisition, with a median time to onset of symptoms of 2-3 days(McFarland, Clarridge, 
Beneda, & Raugi, 2007).  
 C. difficile diarrhea may be associated with the passage of mucus or occult blood in the 
stool, but melena or hematochezia are rare. Fever, cramping, abdominal discomfort, and a 
peripheral leukocytosis are common but found in fewer than half of patients (Cohen et al., 2010). 
C. difficile ileitis or pouchitis has also been rarely recognized in patients who have previously 
undergone a total colectomy (McDonald et al., 2005). Patients with severe disease may develop a 
colonic ileus or toxic dilation and present with abdominal pain and distension but with minimal 
or no diarrhea. Complications of severe C. difficile colitis include dehydration, electrolyte 
disturbance, hypoalbuminemia, toxic megacolon, bowel perforation, hypotension, renal failure, 
systemic inflammatory response syndrome, sepsis, and death (Cohen et al., 2010).  
 
Epidemiology 
 In 2002, the University of Pittsburgh Medical Center in the United States reported an 
increase of severe CDI, which focused attention on rising rates of CDI in Canada, the United 
States, and Europe (Henrich et al).  According to McDonald et al, in 2006, the CDI discharge 
diagnosis rates in U.S hospitals exceeded 300,000 cases per year, which was an increase from 
less than 150,000 in 2000. It is currently estimated that there are approximately 500,000 cases of 
CDI per year in hospitals and long-term care facilities based on annual data from the State of 
Ohio in 2006 (Ohio Department of Health).  
 McDonald et al and others hypothesize that patients are exposed to C. difficile spores 
most often through contact with the hospital environment or health care workers And after taking 
an antibiotic, the person develops CDI if he/she acquires a toxigeneic C. difficile strain and lacks 
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an effective antibody response to the toxins. Lack of preexisting antibodies or timely antibody 
production may result in symptomatic CDI. Alternatively, if antitoxin antibodies are present or 
produced in a timely fashion, the patient may become asymptomatically colonized with C. 
difficile.  Also, acquisition of a non-toxigenic C. difficile strain may lead to asymptomatic 
colonization. Colonized patients have been shown to be protected from CDI.  
 A veterinary model by Asha et al helps to understand the pathogenesis of C. difficile in 
the intestine. C. difficile colonizes the intestine (colon) after disruption of the normal intestinal 
flora. However the roles of adhesion and biofilm production involved in the pathogenesis of C. 
difficile are unknown. The bacterial cells are free to begin with and then attach to host cells. 
Toxigenic strains produce toxin A and toxin B. Toxin B binds to the apical side of the cell and 
after internalization causes cytoskeletal changes that result in disruption of the tight junction, 
loosening the epithelial barrier. The disruption of the junction enables toxins A and B to cross 
the mucosal surface. Both toxins are cytotoxic and induce the release of various 
immunomodulatory mediators resulting in inflammation and the accumulation of neutrophils.  
The local inflammatory effects of CDI result in the formation of “volcano-like” lesions which 
can lead to pseudomembranes that form from the destruction of the intestinal cells and 
leukocytes.  
C. difficile spores 
 C. difficile forms spores that are highly resistant to desiccation, chemical and extreme 
temperatures. Spores frequently contaminate the environment around patients with CDI, 
potentially persisting for months and even years (Ausiello C. M et al). More recently according 
to Fawley W.N et al, a study on cleaning products has  shown spores can survive in the 
temperatures and disinfectant treatment of typical hospital laundering cycles and can cross-
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contaminate bed linens during a wash cycles. In vitro exposure of C. difficile strain to sub-
inhibitory concentrations of non-chlorine-based cleaning agents significantly increased 
sporulation capacity, an effect that is not generally seen with chlorine-based cleaning agents. 
Working-strength concentrations of five different cleaning agents inhibited the growth the C. 
difficile in vitro but only chlorine-based cleaning agents inactivated C. difficile spores.  
Risk Factors 
A number of factors that are known to increase risk for CDI are discussed below.  
Antibiotics 
Historically, the antimicrobials most commonly associated with CDI in well-conducted 
studies are clindamycin, penicillins, and cephalosporins. The increase use of fluoroquinolones 
among both inpatients and outpatients is now a common risk factor for CDI. The use of 
antibiotics are common and many studies have established the risk of antibiotics exposure 
associated with CDI (McDonald et al., 2005). 
The negative effect of antibiotics on the gut flora is a risk factor for CDI. Patients are 
generally resistant to CDI if their normal gut flora is unaltered by antibiotics. Once antibiotic 
treatment begins, infection with a C. difficile strain that is resistant to the antibiotic is more likely 
while the antibiotic is being administered owing to the presence of the antibiotic on the gut. 
When the antibiotic treatment stops, the levels of the antibiotic in the gut diminish rapidly, but 
the microflora remains disrupted for a variable period of time, depending on the antibiotic. 
During this time period, patients can be infected with either resistant or susceptible C. difficile. 
After the microflora recovers from the antibiotic treatment, a process that may take months, 
colonization resistance to C. difficile is restores (Asha et al).  
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A number of recent studies have investigated the risks associated with various antibiotics 
in the development of CDI. Olsen et al reported that 96% of patients with symptomatic C. 
difficile infection had received antimicrobials within the 14 days before the onset of diarrhea and 
that all had received an antimicrobial within the previous 3 months.  
Loo et al performed a case-control study of 237 patients with CDI in 12 Quebec 
hospitals. This study found an odds ratio of 3.9 for receipt of fluoroquinolones in the 
development of CDI and an odds ratio of 3.8 for cephalosporins. Antibiotic resistance testing 
demonstrated widespread fluoroquinolone resistance in the infecting CDI strain. It was proposed 
that frequent fluoroquinolone use contributed to the spread of the CDI NAP1/o27 strain within 
Quebec.  
 Other groups have similarly proposed that outbreaks in their institutions were facilitated 
by an increase in fluoroquinolones usage. Muto et al. describe an outbreak of CDI at a teaching 
hospital in Pittsburg following a change in the antibiotic formulary from ciprofloxacin to 
levofloxacin. Pepin et al analyzed the risk associated with different antibiotics for the 
development of CDI in Quebec and found fluoroquinolones to confer the highest risk and, due to 
their common usage, to also account for the highest population attributable fraction (36%).  
 Gaynes et al., in Atlanta, attributed an outbreak of CDI at a long term care facility to the 
switch in their formulary from levofloxacin to gatifloxacin which has an extended spectrum for 
anaerobic bacteria. This study was conducted to determine the cause of an increase rate of CDI 
in a long term care facility (LTCF). CDI cases were analyzed from October 2001 through June 
2002. Cases were identified from positive enzyme immunoassay for C. difficile toxin A. The 
increase coincided with a formulary change from levofloxacin to gatifloxacin. A case-control 
study used randomly selected control subjects, a variety of risk factors, logistic regression 
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analysis demonstrated associations between CDI and use of clindamycin and gatifloxacin; 
gatifloxacin being associated with an increase of CDI during the outbreak period. In conclusion, 
this study was able to associate the outbreak with a formulary change from levofloxacin to 
gatifloxacin. The rates of CDI declined after a switch back to levofloxacin, concomitant with 
other control measures.  
 
Underlying Condition 
 It was known previously that immunosuppression predisposes an individual to develop 
severe CDI. There have been, however, few controlled studies of CDI risk in HIV infection. 
Sanchez reviewed data from the Adult/ Adolescent Spectrum of HIV Disease (ASD) Project and 
found that C. difficile was the most commonly isolated bacterial cause of diarrhea in individuals 
with HIV during 1992-2002, accounting for 598 of 1115 (53.6%) bacterial agents identified. This 
high CDI risk is likely to be the result of frequent prophylactic and therapeutic antibiotic courses 
in HIV-infected individuals as well as their frequent visits to healthcare facilities.   
 A study by Nylund et al suggests an increase in CDI infection among hospitalized 
children, especially those hospitalized with medical conditions such as inflammatory bowel 
disease and immunosuppression. Also at risk are those hospitalized with conditions that require 
antibiotic administration. 
  
Age 
 C. difficile is more common in elderly people, and old age may promote susceptibility to 
colonization and disease (Asha et al).  While infants and young children frequently harbor C. 
difficile and its toxins, clinical infection is uncommon.  More recently there have been reports of 
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populations affected by C. difficile that would normally be considered low risk. These 
populations include young healthy persons not exposed to a hospital environment or 
antimicrobial therapy and young pregnant women in the peripartum setting.  
  There is a high incidence and increased mortality among older patients that is attributed 
to the failure of these individuals to create an effective immune response when first exposed to 
the C. difficile toxins. This lack of immune response has also been associated with higher rates of 
recurrent disease (Kyne et al).  
 
Residence 
Community Associated 
 The Morbidity and Mortality Weekly Report of December 2005 highlighted concerning 
reports of severe CDI in individuals previously considered at low risk. The CDC investigated 
cases reported in peripartum women and cases of community acquired CDI. Voluntary 
participants were requested to report peripartum CDI cases nationally through epi-X, and locally 
in Pennsylvania and New Jersey for community acquired CDI during May and June of 2005. 10 
peripartum CDI cases and 23 community acquired CDI cases were reviewed. Eight of the 33 
patients had no documents exposure to antibiotics in the three months before onset of disease. 
Three of the eight had close contact with someone with a diarrheal illness and two isolates were 
available for strain typing, both stools detected excess toxins A and B.  
 In the United Kingdom Dial et al examined the development of community acquired 
CDI. This large population case-control study examined gastric acid suppressive agents as a risk 
factor for the development of CDI. The authors identified 1233 patients with CDI who had not 
been hospitalized in the year prior to diagnosis and were therefore considered to have community 
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acquired CDI. Of the 833 patients who were diagnosed with the infection based on a positive 
toxin assay, only 284 (34%) had a documented history of antibiotic use within 90 days prior to 
diagnosis. These findings were in contrast with nosocomial CDI, for which the vast majority of 
patients have a history of recent antibiotic use. 
  
Health Care Facility Associated 
 According to Miller et al hospitalization and exposure to a healthcare facility is a risk 
factor for the acquisition of CDI for many reasons. Healthcare exposure multiples the risk of CDI 
because it increases the likelihood of exposure to antibiotics, spore-contaminated environments, 
inadequate hand hygiene by health care workers and a highly susceptible elderly population of 
patients that may be hospitalized.  
 A study by Archibald et al addresses the rates of CDI in hospital settings. The authors 
reviewed C. difficile associated disease data from intensive care units (ICU) and hospital wide 
surveillance components of the National Nosocomial Infections Surveillance system hospitals 
during 1987- 2001. ICU CDI rates increased significantly in hospitals with more than 500 beds 
(p<.01) and correlated with the duration of ICU stay. CDI was highest in general hospitals versus 
other facility types, and the rates were significantly higher in winter months versus non-winter 
months (p<0.1). 
 Campbell et al described the disease burden and mortality rate of healthcare-onset CDI, 
suggesting that the incidence and severity of CDI is increasing in healthcare-related 
establishments. In 2006, active public reporting of healthcare-onset CDI was mandated for all 
Ohio hospitals and nursing homes. Incident rates were determined and stratified according to 
healthcare facility characteristics and death certificates that listed CDI were analyzed. There 
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were a total of 14,329 CDI cases reported, including 6,376 at 210 hospitals. The rate for initial 
cases was 6.4-7.9 cases/10,000 patient-days for hospitals and 1.7-2.9 cases/10,000 patient-days 
for nursing homes. Death certificates for 2006 listed CDI among the causes of death for 893 
Ohio residents; between 2000-2006 this number increased more than 4-fold.  
 A case control study conducted in 1993 by Barbut et al looked at determining the 
prevalence of C. difficile in stool specimens of hospitalized patients sent to hospital microbiology 
laboratories, to assess the relationship between serotypes and toxigenicity of the strains isolated, 
and evaluate the clinical data. The presence of C. difficile was systematically investigated from 
January 1993- July 1993 by looking at 3921 stool samples sent for stool cultures to 11 French 
hospital microbiology laboratories. The prevalence in this population was compared with that of 
a group of 220 random hospital controls matched for age, department, and length of stay. Stool 
cultures from controls were collected by laboratory personnel for the purposes of the study; 
serotype and toxin production of the strains were determined and compared. Overall the 
prevalence of C. difficile in the cases were two times more than in the control group, and 
approximately 4 times as high in diarrheal stools compared to normally formed stools from 
controls.  Strains were more frequently toxigenic in loose stools than those isolated from 
normally formed stools. Serotype C was more commonly found in patients, older than 65 years 
of age and those suffering from severe disabling disease, who had been treated with antibiotics 
and hospitalized for more than 1 week.  
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CHAPTER III 
Methods 
Patient Selection 
Patients were identified through the Clostridium difficile Surveillance Program of the 
Georgia Emerging Infections Program (EIP). Since September of 2009 the GA EIP has 
performed prospective, population-based, laboratory-based surveillance for all the positive C. 
difficile cases in Georgia Health District 3 (HD3), the 8-county Atlanta metropolitan area. All 
residents aged one year and older in the surveillance areas from whom a positive C. difficile 
toxin enzyme immunoassay (EIA) or positive C. difficile nucleic acid assay (e.g PCR) from 
human stool or an ileostomy specimen was obtained were eligible for investigation. Clinical 
laboratories in the surveillance area, on a monthly basis, will provide a line list of positive C. 
difficile toxin assay test results and patient identifying information. Each positive assay result 
was cross-checked with a dataset containing previous line lists positive C. difficile toxin tests to 
determine if episodes were a duplicate, recurrent, or incident CDI case. A case of CDI was 
defined as a positive C. difficile test on an incident stool specimen. Cases with a positive stool 
specimen for C. difficile greater than 8 weeks after the last positive specimen were considered a 
new case (Baughman et al). 
Study personnel retrospectively reviewed medical records using a standardized case 
report form (CRF) to abstract data on demographics, clinical characteristics, and outcomes. 
Cases were classified in to 3 categories: Healthcare Facility Onset (HCFO), Community Onset 
Healthcare Facility Associated (COHCFA), or Community Associated (CA). HCFO is defined as 
a case with the initial C. difficile positive specimen collected greater than four calendar days after 
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admission to a healthcare facility (i.e. acute care hospital, long-term care acute hospital, long 
term care facility).  Community onset cases with an overnight stay at a healthcare facility in the 
twelve weeks prior to initial positive C. difficile result were classified as CO-HCFA. Cases with 
community onset without a documented overnight stay in a healthcare facility in the twelve 
weeks prior to initial positive specimen collection were classified as CA (Baughman et al).  
Due to the high volume of positive C. difficile assays present in this population, a 
stratified random sampling scheme was used and cases were stratified by age and gender except 
for the youngest age group of males and females 1-17. All cases occurring in those 1-17 years of 
age were included in the analysis. For the remaining groups, male and females 18-44, 45-64, 
>65, only 1:3 CDI cases were sampled and a CRF was completed on those sampled (except 
September 2009 and October 2009). In the classification of HCFO, 1:10 cases were randomly 
selected for CRF completion (Baughman et al). Figure 1 represents a breakdown of the case 
selection used for analysis. 
Due to the sampling scheme, for this analysis the classifications COHCFA and HCFO 
were combined to make a Healthcare Facility Associated (HCFA) category. Therefore the 
outcomes being described are CA and HCFA. The underlying conditions and antibiotics were 
grouped to form classifications for analysis (see appendix 1 and 2 for table representing the 
combinations). 
Statistical Analysis 
The study period for this analysis was from September 1, 2009 through April 30, 2011. 
Statistical analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC). A logistic 
regression was performed to identify risk factors significantly associated with the specified 
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outcomes. In addition, a chi squared analysis was then performed to evaluate the impact of being 
on no, one, or two or more antibiotics versus. The same analysis was performed for underlying 
conditions to see if a patient with CDI was more likely to have none, one, or two or more 
underlying conditions. Odds Ratios were also calculated to compare HCFA-CDI cases to CA-
CDI cases when specifically looking at the relationships between either no antibiotics or no 
underlying condition compared to an individual antimicrobial classification or underlying 
condition group.  
IRB 
This study was approved by the Georgia State University (Protocol #H12310) and Emory 
University’s (Protocol #5558.0) IRBs, and the VA Research and Development Committee 
(Protocol #16622).  
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Figure 1: Flow Chart demonstrating the sample method used for this study.
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CHAPTER IV 
Results 
Between September 1, 2009 and April 30, 2011, 5244 incident cases were identified by 
the GA EIP surveillance project. The incident rate of CDI in the Metro Atlanta population was 
84 cases per 100,000 calculated using all incident cases in 2010 compared to 2010 census data. 
The median age was 63, with ages ranging from 1 to 102, and 61% of the cases studies were 
female.  
Demographics of cases included in the study are shown in Table 1. In addition, 38% of 
the cases had no healthcare facility association and a majority of this sample was White/ Non-
Hispanic (48%). Looking at the CA cases, the column percents show a similar distribution 
among age groups where in the CO-HCFA and HCFO the distribution of cases increase with age.  
TABLE1 Description of Cases, September 2009 – April 2011 
 
    CA               
n=837          
(38%) 
(col %) 
CO-HCFA 
n=413             
(19%) 
(col %) 
HCFO 
n=938             
(43%) 
(col %) 
Total (%) 
Age           
  1-17 208 (25) 30 (7) 15 (1.6) 253 (12) 
  18-44 179 (21) 65 (16) 81 (8.6) 325 (15) 
  45-64 237 (28) 103 (25) 231 (25) 568 (26) 
  65+ 214 (26) 215 (52) 611 (65) 1039 (47) 
Sex           
  Male 315 (38) 172 (42) 371 (40) 855 (39) 
  Female 523 (62) 241 (58) 567 (60) 1330 (61) 
Race/ Ethnicity         
  White/NH 308 (64) 228 (63) 516 (59) 1050 (48) 
  Black/NH 151 (32) 114 (32) 344 (39) 607 (28) 
  Hispanic 19 (4) 18 (5) 15 (2) 52 (2) 
  Other 9 6 12 27 (1) 
  Unknown 351 47 51 449 (21) 
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After the additional 1:10 HCFO sample, the case study population size reduced to 1314. 
Of the 938 HCFO cases, only 65 CRFs were completed due to the sampling method. Completed 
HCFO cases were combined with the CO-HCFA cases to make a HCFA-CDI group. Table 2 
represents a description of the 1314 cases considered for analysis. The age group 65 years and 
older are significantly more likely to have a HCFA-CDI compared to CA-CDI group (p<0.01). 
TABLE 2 Univariate Descriptions of 
Demographics
    CA (reference) 
n=837 
HCFA 
n=477 
p-value 
Age         
  1-17 (reference) 208 30   
  18-44 179 72  
  45-64 237 120  
  65+ 213 255 0.0013 
Sex         
  Male (reference) 314 198   
  Female 523 280 0.5095 
Race/ Ethnicity       
  White/NH (reference) 307 266   
  Black/NH 151 136 0.1979 
  Hispanic 19 18 0.0448 
 
 
Of the antibiotics that were examined, a univariate chi square analysis was performed to 
determine which antibiotic classifications were more of a risk factor for the HCFA-CDI group 
compared to the CA-CDI group (Table 3). Using no antibiotic exposure 14 days prior to stool 
collection as a reference group, fluoroquinolones, cephalosporins, and Vancomycin were 
significantly associated with the HCFA-CDI group compared to the CA-CDI group (p values 
<0.01). Among the underlying condition groups reviewed, a univariate chi square analysis 
determined that HIV/AIDS, cardiovascular disorders, neurological disorders, other chronic 
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conditions, and diabetes were significantly more associated with HCFA-CDI cases compared to 
CA – CDI cases.  
TABLE 3 Univariate Analysis of Antibiotics 
 Antibiotics CA  
(%) 
HCFA 
(%) 
p-value 
(chi sq) 
None 395 (47) 185 (39) 0.0032 
Fluoroquinolones 50 (7) 100 (21) <0.0001 
Cephalosporins 58 (7) 60 (13) 0.0006 
Metronidazole 64 (8) 55 (12)  
Vancomycin 18 (2) 52 (11) <0.0001 
Penicillins & Carbopenems 76 (9) 48 (10)  
Clindamycin 26 (3) 6 (1)  
Macroloids 23 (3) 20 (4)  
 
 
TABLE 4 Univariate Analysis of Underlying Conditions 
 Underlying 
Conditions 
CA 
 (%) 
HCFA 
 (%) 
p-value 
(chi sq) 
None 434 (52) 73 (15) <0.0001 
HIV/AIDS 21 (3) 25 (5) 0.0096 
Gastrointestinal 112 (13) 57 (12)  
Cardiovascular 38 (5) 106 (22) <0.0001 
Neurological 37 (4) 84 (18) <0.0001 
Tumors 54 (6) 47 (10)  
Other Chronic 118 (14) 211 (44) <0.0001 
Diabetes 81 (10) 129 (27) <0.0001 
 
 
An array function in SAS was used to determine the number of cases that were taking 
antibiotics 14 days prior to a positive stool or the number of underlying conditions an individual 
had. More HCFA-CDI cases (8%) were taking two or more antibiotics compares to CA-CDI 
cases (6%). In addition, there were more HCFA-CDI cases (16%) that had two or more 
underlying conditions compared to the CA-CDI group (9%).  
 
 
 
22 
 
TABLE 5 Logistic Regression of Antibiotics 
    
 
 
 
 
 
TABLE 6 Logistic Regression of Underlying Conditions 
Risk Factors CA (reference) HCFA p-value 
Underlying Conditions       
  None (reference) 434 73   
  HIV/AIDS 14 9 0.0448 
  Gastrointestinal  79 29 0.0219 
  Cardiovascular 8 24 <0.0001 
  Neurological 22 32 <0.0001 
  Tumor 35 30 <0.0001 
  Other Chronic 83 126 <0.0001 
  Diabetes 81 129 <0.0001 
  Unknown 62 8 0.9035 
 
A multivariate logistic regression was then used to determine the difference between the 
HCFA-CDI group compared to the CA-CDI group among the different risk factors (reference 
tables 5 and 6). The HCFA-CDI group was significantly more likely to be taking the following 
antibiotics 14 days prior to a positive stool collection: Cephalosporins, Metronidazole, and 
Vancomycin (p <0.01) compared to no antibiotic use the CA-CDI group. The HCFA-CDI group 
Risk Factors CA (reference) HCFA p-value 
Antibiotics       
  None (reference) 395 185   
  Fluoroquinolones 27 44 0.0392 
  Cephalosporins 23 28 0.0041 
  Metronidazole 41 41 0.0026 
  Vancomycin 13 32 0.0008 
  Penicillins & Carbopenems 60 35 0.0959 
  Clindamycin 25 5 0.5603 
  Macroloids 17 15 0.1585 
  Other 118 55 0.4135 
  Unknown 116 36 0.6549 
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was also significantly more likely to have the following underlying conditions, Cardiovascular, 
Neurological diseases, Tumor, Other Chronic diseases, and Diabetes compared to no underlying 
condition in the CA-CDI group.  
TABLE 7 Odds Ratio of Demographic 
Risk Factor  Odds Ratio (95% Wald CI) 
Age   
 1-17 (reference) 1 
 18-44 1.7 (0.959, 2.896) 
 45-64 1.5 (0.877, 2.587) 
 65+ 2.4 (1.414, 4.193) 
Sex   
 Male (reference) 1 
 Female 0.9 (0.682, 1.209) 
Race Ethnicity   
 White N/H (reference) 1 
 Black N/H 1.2 (0.889, 1.763) 
 Hispanic 2.2 (1.006, 4.996) 
 
 
TABLE 8 Odds Ratio of Antibiotics 
Risk Factor  Odds Ratio (95% Wald CI) 
Antibiotics   
 None (reference) 1 
 Vancomycin 3.7 (1.716, 7.838) 
 Cephalosporin 2.8 (1.382, 5.576) 
 Metronidazole 2.3 (1.347, 4.089) 
 Fluoroquinolones 1.9 (1.032, 3.497) 
 Macroloids 1.9 (0.785, 4.410) 
 Penicillins & Carbopenems 1.6 (0.922, 2.704) 
 Clindamycin 0.7 (0.246, 2.136) 
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TABLE 9 Odds Ratio of Underlying Conditions 
Risk Factor  Odds Ratio (95% Wald CI) 
Underlying Conditions   
 None (reference) 1 
 Cardiovascular 10.9 (4.498, 26.805) 
 Other Chronic 6.2 (4.068, 9.367) 
 Diabetes 5.4 (3.484, 8.251) 
 Neurological 3.9 (2.006, 7.556) 
 Tumors 3.6 (1.978, 6.469) 
 HIV/AIDS 2.6 (1.022, 6.678) 
 Gastrointestinal 1.9 (1.095, 3.200) 
 
 
An odds ratio was also calculated through the logistic regression and the outputs are 
viewed in tables 7, 8, and 9. Table 7 shows that the HCFA-CDI group was 2.4 times more likely 
to be 65 or older than the CA-CDI group (C.I 1.414, 4.193). The HCFA-CDI group was also 3.7 
times more likely to be taking Vancomycin (C.I 1.716, 7.838), 2.8 times more likely to be taking 
Cephalosporins (C.I 1.382, 5.576), 2.3 times more likely to be taking Metronidazole (C.I 1.347, 
4.089), and 1.9 times more like to be taking Fluoroquinolones (C.I 1.032, 4.410) than the CA-
CDI group (table 8). The HCFA-CDI group is significantly more likely to have an underlying 
condition compared to the CA-CDI group (table 9). The HCFA-CDI group is 10.9 times more 
likely to have a cardiovascular disorder (C.I 2.298, 26.805), 6.2 times more likely to have 
another Chronic disorder (C.I 4.068, 9.367), 5.4 times more likely to have Diabetes (C.I 3.484, 
8.251), 3.9 times more likely to have a Neurological disease (C.I 2.006, 7.556), 3.6 times more 
likely to have a Tumor (1.978, 6.469), 2.6 times more likely to have HIV/AIDS (C.I 1.022, 
6.678), and 1.9 times more likely to have a Gastrointestinal disorder (C.I 1.095, 3.200) compared 
to the CA-CDI group. 
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CHAPTER V 
Discussion  
This study shows a significant difference in HCFA-CDI cases compared CA-CDI cases 
where HCFA-CDI is more associated with antimicrobial exposure 14 days prior to a positive 
stool collection and is more likely to have an underlying condition compared to the CA-CDI 
group. Although there is little comparable data on trends of community-associated compared to 
healthcare facility associated CDI in an urban setting, literature supports the findings that 
antibiotics and underlying conditions are risk factors for CDI (Asha, et al; Henrich et al, 2009). 
In addition, literature supports that healthcare facility associated infections are more likely to 
have exposure to antibiotics than cases not exposed to a healthcare facility (Thomas, Stevenson, 
& Riley, 2003).  
The objective of this study was to describe C. difficile infection in the Atlanta population. 
Based on literature review, it was predicted that healthcare facility associated CDI cases would 
have greater associations of being on antibiotics 14 days prior to stool collection and have at 
least one underlying condition. After conducting the analysis, this hypothesis was proven to be 
correct. In addition, the rate of CDI infection based on 2010 incident cases, using the 2010 
census data as the denominator, was calculated and determined to be 84 cases per 100,000 
people. 
The significance of antimicrobial associations was lower in the HCFA-CDI group than 
the expected based on literature review regarding particular classes of antibiotics. Based on the 
literature clindamycin, penicillins, cephalosporins, and fluoroquinoles are the most common 
antibiotics associated with CDI (McDonald). Clindamycin has shown to be associated with CDI 
due to clindamycin- resistant, toxigenic strains of C. difficile (Owens et al., 2008). In this 
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analysis, clindamycin did not have a significant association to CDI. This also may be true since 
clindamycin has been on the decline after being associated with so many C. difficile outbreaks 
(Owens et al., 2008). This seems to be the case for cephalosporins, which were targeted as risk 
factors for CDI and also related to outbreaks. Second and third generation cephalosporins were 
identified as chief risk factors for a C. difficile outbreak in a Veterans Administration medical 
center in New York (Owens et al., 2008). The literature supports cephalosporins as being a risk 
factor for CDI, my results support the literature on cephalosporins have a significant association 
of CDI. The literature also suggests that fluoroquinolones are associated with CDI outbreaks. C. 
difficile is a hardy bacterium that has become resistant to these antimicrobial agents (Asha et al., 
2006). My results, however, supported a significant association of fluoroquinolone use in a 
univariate analysis, but no significant association in a multivariate analysis. Metronidazole and 
Vancomycin are antibiotics suggested for the treatment of CDI (Cohen et al., 2010). My results 
indicate that Metronidazole and Vancomycin are significantly being used in cases that have CDI 
14 days prior to stool collection. Moving forward it will be interesting to see how Metronidazole 
and Vancomycin play a role in risk factors for CDI. The rates of antimicrobial resistant 
infections are on the rise, since these two drugs are most commonly used as treatment for CDI, 
public health precautions need to be considered to reduce the Metronidazole and Vancomycin 
exposure to patients without C. difficile.  
Of studies that have been conducted solely on healthcare facility onset CDI, the co-
morbidity of patients reflects similar findings to what this study presents, where chronic 
conditions are associated with HCFA-CDI (Fawley, 2007). Underlying conditions found to be 
associated with CDI in this study that differ from the current literature include cardiovascular 
diseases, Neurological diseases, Tumors, Other Chronic diseases, and Diabetes. Underlying 
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conditions found not to have a significant association with CDI that the literature suggested 
would include Immunosuppressive disorders and gastrointestinal disorders. There are no current 
hypotheses for why these two are not significant in this analysis.  
Studies suggest than an increase in age puts patients at a  higher risk of CDI than those younger 
than 65 (Kutty et al., 2010). The results from this study support literature in that patients 65 and 
older were more likely to have CDI than the younger age groups. In addition, the analysis 
concluded that CDI cases older than 65 are significantly more likely to be HCFA compared to 
CA.  
This study represents an initial analysis on a specific population based on a surveillance 
system put in place via the Centers for Disease Control and Prevention and the Emerging 
Infections Program. This analysis can be used as a base line moving forward with surveillance 
for the metropolitan Atlanta area regarding rates of C. difficile in a population and risk factors 
associated with the infection. As the surveillance continues additional analysis can be conducted 
to analyze severity of infection among case classifications. Furthermore, it would be interesting 
to continue analysis on the antimicrobial associations with CDI in the Atlanta area, by continuing 
surveillance and data collection for antibiotics taken 14 days prior to stool collection, trends can 
be monitored to see if new resistance is forming based on the behavior of the clinical groups and 
hospitals in Atlanta.  
There were limitations to this study. To begin with, the sampling scheme made initial 
analysis difficult due to the 1:3 sampling of all incident cases, then the additional 1:10 sample of 
HCFO cases. Initially, comparing the three groups would have been interesting, but due to the 
1:10 HCFO sample, that population was too small to conduct an accurate analysis. In addition, 
proper weighting has not been established to make up for the small sample numbers. This study 
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also does not adjust for the 1:3 sampling scheme, so this data is representative of a third of the 
CDI population. In addition, the population analysis only consisted of those who had CDI, 
therefore comparing CDI cases to CDI cases made analysis less straight forward for determining 
the outcome variable.  
The rate of C. difficile in the population being observed is higher than the rate of C. 
difficile in the United States, 76 per 100,000 (Redelings et al., 2007). CDI seems to be increasing 
over time which is either due to better testing methods, better surveillance, or an increase of 
cases (Redelings et al., 2007). To prevent C. difficile in the population a number of actions can 
be taken to reduce the incidence of CDI.  First of all, hand washing and hygiene is very 
important, especially in the healthcare facility environment or when exposed to someone who 
has severe diarrhea. Secondly, reduce the amount of antibiotics that are prescribed in both 
inpatient and outpatient settings. This can be done by assuring that antibiotics are given after 
results of a positive culture for the assumed infection or disease. This leads in to the practice of 
antimicrobial stewardship, which is the approach to preventing emergence of antimicrobial 
resistance. According to a study by Fishman et al, 50% of antibiotics are prescribed 
unnecessarily. This also includes better physician – patient interaction, where patients are 
educated about the medications they are taking for their underlying conditions or antibiotics they 
are on for specific infections. Combinations of these underlying conditions and antibiotics may 
pose a higher risk for CDI. A third suggestion would be to conduct as a case control study, both 
looking at CA-CDI cases matched to a community control, and HCFA-CDI cases matched to a 
healthcare facility control. By conducting a case control interview, additional risk factors among 
the groups will become clearer as to why some people are getting CDI and some are not. 
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Conclusion 
This study represents an analysis of one third of the CDI cases in the metro-Atlanta 
population. Surveillance on C.difficile is important as the Antimicrobial Resistance Infections are 
becoming more common. From this study we know that age greater than 65, being on antibiotics, 
and having an underlying condition are risk factors for HCFA-CDI cases compared to CA-CDI 
cases. The risk increases as patients are taking more than one antibiotic and have more than one 
underlying condition (p< 0.0001). Therefore, it is important to reduce the risk of exposure of C. 
difficile by using prevention methods discussed. 
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Background
 Clostridium Difficile (C. Diff) is an 
anaerobic, spore-forming, toxigenic 
bacteria that is the most commonly 
recognized cause of infectious 
nosocomial diarrhea and one of the 
most common healthcare-associated 
pathogens 
 CDI = C. diff Infection
www.bioquellus.com
3  
Clinical Manifestation
 Symptoms
 Asymptomatic to mild or moderate diarrhea 
to fulminate or fatal colitis
 Acquisition (a hypothesis)
4
Asymptomatic 
C. difficile
colonization
C. difficile exposure
Antimicrobial
C. difficile
infectionGerding DN,  Discov Med. 2012; 13 (68):75-83
Slide Courtesy of Dale Gerding, Hines VA
Hospitalization
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Pathogenesis
Sunenshine et al. Cleve Clin J Med. 2006;73:187-97.
4. Toxin A & B Production
leads to colon damage 
+/- pseudomembrane
1. Ingestion
of spores transmitted 
from other patients 
via the hands of healthcare 
personnel and environment
2. Germination into
growing (vegetative)
form
3. Altered lower intestine flora 
(due to antimicrobial use) allows 
proliferation of 
C. difficile in colon
 
Risk Factors: Antibiotics
 The negative effect of antibiotics on the 
gut flora is a risk for CDI
 96% of patients with CDI received 
antimicrobials within the 14 days before 
the onset of diarrhea and all had 
received antimicrobial therapy within the 
previous 3 months (Olsen et al)
 Most common antimicrobial exposures: 
Clindamycin, penicillins, cephalosporins, 
& fluoroquinolones (McDonald)
6  
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Risk Factors: Underlying 
Conditions
 CDI was the most commonly isolated 
bacterial cause of diarrhea in individuals 
with HIV (Sanchez1992-2002).
 An increase in CDI was associated with 
hospitalized children with severe medical 
conditions such as IBD and 
Immunosuppressive diseases (Nyland). 
7  
Risk Factor: Age
 Several studies suggest CDI is more 
common in elderly people and old age 
may promote susceptibility
 High incidence and increased mortality 
among older patients attributed is to the 
failure of these individuals to create an 
effective immune response when first 
exposed to C. difficile toxins. 
8  
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Healthcare Facility 
Associated  (HCFA) CDI
 Hospitalization and exposure to 
healthcare facilities is a risk factor for 
acquisition for CDI (Miller et al).
 In 2006, in Ohio, 14,329 healthcare 
Onset CDI cases were reported in 210 
hospitals (Ohio Dept of Public Health).
9  
Community Associated (CA) 
CDI
 Populations now affected by CDI that would 
normally be at low risk
 In a large UK study, 34% of the non-
hospitalized CDI diagnosis in the community 
had documented prior antibiotic use in 
previous 90 days (Dial et al)
10  
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Objectives & Hypothesis
 Objective
 Examine the differences in antimicrobial use 
and underlying conditions in CA vs HCFA 
CDI.
 H0
 There will be no difference in antimicrobial 
use and underlying condition between the 
CA and HCFA groups. 
11  
12  
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Case Identification
 Identified through Clostridium difficile 
Surveillance Program at the Georgia 
Emerging Infections Program. 
 Case Definition
 Positive Toxin Assay
 Age
 HD3
13  
Case Identification
 HD3
 Pop ~ 3.7 million
○ Clayton
○ Cobb
○ Dekalb
○ Douglas
○ Fulton
○ Gwinnett
○ Newton
○ Rockdale
14  
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Case Report Forms (CRFs)
15  
Data Collected from CRFs
Variables of Interest
16  
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CDI Case Classifications
 Community Associated (CA)
 Community onset without a documented overnight stay in a healthcare facility in the 
12 weeks prior to initial positive C. diff stool
 Community Onset – Healthcare Facility 
Associated (COHCFA)
 Community onset cases with an overnight stay at a healthcare facility in the 12 
weeks prior to initial positive C. diff stool
 Healthcare Facility Onset (HCFO)
 Case with initial C. diff positive specimen collected greater or equal to 4 calendar 
days after admission to a healthcare facility (acute care hospital, LTAC, LTCF, SNF)
17  
18
 
All CDI Incident Cases in HD3 
Catchment  
(September 1, 2009 – 
 April 30, 2011) 
N = 5244 
September 1, 2009 –  
October 31, 2009 
All Cases 
N1= 453 
 
November 1, 2009 – 
 April 30, 2011 
1:3 Sampled 
N2 = 1770 
HCFO1 
N=214 
COHCFA1 
N=87 
CA1 
N= 134 
HCFO2 
N= 724 
COHCFA2 
N= 326 
CA2 
N= 704 
HCFO1 
1:10 
Sample 
N=9 
HCFO2 
1:10 
Sample 
N=56 
COHCFA1 
N=87 
CA1 
N= 134 
COHCFA2 
N= 326 
CA2 
N= 704 
HCFO1+2 
N=65 
COHCFA1+2 
N=413 
CA1 
N= 134 
CA2 
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Statistical Analysis
 SAS Programming
 Univariate
 Logistic Regression
19  
20  
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Rate of CDI in HD3, 2010
 3067 Incident cases in 2010 in a 
population of 3,630,152 for an annual 
rate of 84 cases per 100,000.
 Cases ranged in age from 1-102 (mean 
56, median 63)
21  
Description of Cases, Sept 
2009- April 2011
22
 
    CA               
n=837          
(38%) 
(col %) 
CO-HCFA 
n=413             
(19%) 
(col %) 
HCFO 
n=938             
(43%) 
(col %) 
Total (%) 
Age           
  1-17 208 (25) 30 (7) 15 (1.6) 253 (12) 
  18-44 179 (21) 65 (16) 81 (8.6) 325 (15) 
  45-64 237 (28) 103 (25) 231 (25) 568 (26) 
  65+ 214 (26) 215 (52) 611 (65) 1039 (47) 
Sex           
  Male 315 (38) 172 (42) 371 (40) 855 (39) 
  Female 523 (62) 241 (58) 567 (60) 1330 (61) 
Race/ Ethnicity         
  White/NH 308 (64) 228 (63) 516 (59) 1050 (48) 
  Black/NH 151 (32) 114 (32) 344 (39) 607 (28) 
  Hispanic 19 (4) 18 (5) 15 (2) 52 (2) 
  Other 9 6 12 27 (1) 
  Unknown 351 47 51 449 (21) 
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Description of Cases, Sept 
2009- April 2011
23
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Description of Cases, Sept 
2009- April 2011
25
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Univariate Descriptive 
Analysis
26
    CA (reference) 
n=837 
HCFA 
n=477 
p-value 
Age         
  1-17 (reference) 208 30   
  18-44 179 72  
  45-64 237 120  
  65+ 213 255 0.0013 
Sex         
  Male (reference) 314 198   
  Female 523 280 0.5095 
Race/ Ethnicity       
  White/NH (reference) 307 266   
  Black/NH 151 136 0.1979 
  Hispanic 19 18 0.0448 
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Univariate Analysis
27
 Antibiotics CA  
(%) 
HCFA 
(%) 
p-value 
(chi sq) 
None 395 (47) 185 (39) 0.0032 
Fluoroquinolones 50 (7) 100 (21) <0.0001 
Cephalosporins 58 (7) 60 (13) 0.0006 
Metronidazole 64 (8) 55 (12)  
Vancomycin 18 (2) 52 (11) <0.0001 
Penicillins & Carbopenems 76 (9) 48 (10)  
Clindamycin 26 (3) 6 (1)  
Macroloids 23 (3) 20 (4)  
 
 
Univariate Analysis
28
 Underlying 
Conditions 
CA 
 (%) 
HCFA 
 (%) 
p-value 
(chi sq) 
None 434 (52) 73 (15) <0.0001 
HIV/AIDS 21 (3) 25 (5) 0.0096 
Gastrointestinal 112 (13) 57 (12)  
Cardiovascular 38 (5) 106 (22) <0.0001 
Neurological 37 (4) 84 (18) <0.0001 
Tumors 54 (6) 47 (10)  
Other Chronic 118 (14) 211 (44) <0.0001 
Diabetes 81 (10) 129 (27) <0.0001 
 Other Chronic includes: Chronic Pulmonary Disease, Chronic Liver 
Disease, & Chronic Renal Insufficiency
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Risk Factor Index
 
Co-Morbidity Index    
 CA HCFA Total 
0 515 98 613 
1 209 171 380 
>2 113 208 321 
 
Antibiotic Use Index    
 CA HCFA Total 
0 557 237 794 
1 202 135 337 
>2 78 105 183 
29  
Analysis: Logistic 
Regression
30
 
Risk Factors CA (reference) HCFA p-value 
Antibiotics       
  None (reference) 395 185   
  Fluoroquinolones 27 44 0.0392 
  Cephalosporins 23 28 0.0041 
  Metronidazole 41 41 0.0026 
  Vancomycin 13 32 0.0008 
  Penicillins & Carbopenems 60 35 0.0959 
  Clindamycin 25 5 0.5603 
  Macroloids 17 15 0.1585 
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Analysis: Logistic 
Regression
31
 
Risk Factors CA (reference) HCFA p-value 
Underlying Conditions       
  None (reference) 434 73   
  HIV/AIDS 14 9 0.0448 
  Gastrointestinal  79 29 0.0219 
  Cardiovascular 8 24 <0.0001 
  Neurological 22 32 <0.0001 
  Tumor 35 30 <0.0001 
  Other Chronic 83 126 <0.0001 
  Diabetes 81 129 <0.0001 
 
Analysis: Odds Ratio
32
Risk Factor  Odds Ratio (95% Wald CI) 
Age   
 1-17 (reference) 1 
 18-44 1.7 (0.959, 2.896) 
 45-64 1.5 (0.877, 2.587) 
 65+ 2.4 (1.414, 4.193) 
Sex   
 Male (reference) 1 
 Female 0.9 (0.682, 1.209) 
Race Ethnicity   
 White N/H (reference) 1 
 Black N/H 1.2 (0.889, 1.763) 
 Hispanic 2.2 (1.006, 4.996) 
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Analysis: Odds Ratio
33
Risk Factor  Odds Ratio (95% Wald CI) 
Antibiotics   
 None (reference) 1 
 Vancomycin 3.7 (1.716, 7.838) 
 Cephalosporin 2.8 (1.382, 5.576) 
 Metronidazole 2.3 (1.347, 4.089) 
 Fluoroquinolones 1.9 (1.032, 3.497) 
 Macroloids 1.9 (0.785, 4.410) 
 Penicillins & Carbopenems 1.6 (0.922, 2.704) 
 Clindamycin 0.7 (0.246, 2.136) 
 
 
Analysis: Odds Ratio
34
Risk Factor  Odds Ratio (95% Wald CI) 
Underlying Conditions   
 None (reference) 1 
 Cardiovascular 10.9 (4.498, 26.805) 
 Other Chronic 6.2 (4.068, 9.367) 
 Diabetes 5.4 (3.484, 8.251) 
 Neurological 3.9 (2.006, 7.556) 
 Tumors 3.6 (1.978, 6.469) 
 HIV/AIDS 2.6 (1.022, 6.678) 
 Gastrointestinal 1.9 (1.095, 3.200) 
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35  
Discussion
 Significant findings
 Age
○ Known= Age
 Antibiotics
○ Known= Fluoroquinolones, Clindamycin*, 
Cephalosporins, Penicillins
○ Unknown= Metronidazole & Vancomycin
 Underlying Conditions
○ Known = HIV / Gastrointestinal*
○ Unknown = everything else
36  
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Discussion
 Clindamycin
 Dr. Ray, Grady HAI Study 
 Gastrointestinal Diseases
 Reasons for being insignificant
○ HCFO, 1:10 Sample – causing under-
representation.
37  
Strengths & Limitations
 Strengths
 One of a few studies that analyzes a 
population based surveillance data focusing 
on community acquired infection.
 Limitations
 The Sampling! 
 First person to analyze the GA CDI data
 CA case data collection by Chart Reviews 
only.
 Difficult to make findings generalizable. 
38  
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CDI Prevention
 Hand washing and hygiene
 Especially in the healthcare facility 
environment or when exposed to someone 
with diarrhea
 Specific hand washing technique
 Reduce Antibiotics that are prescribed in 
both inpatient and outpatient settings
 According to Fishman 50% of antibiotics are 
prescribed unnecessarily. 
39  
Suggestions for Future 
Studies
 Conduct a Case – Control study (CDC 
planning to start 2014)
 Collect additional information on CRF’s 
including antibiotics taken 3 months 
prior vs. 14 days prior to positive stool 
collection (beginning with all 2012 
cases- BAM!)
40  
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41  
I’m ready for your…
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